Baron and Budd Lists Qualifications for Participating in GranuFlo Lawsuit

Wed Aug 7, 2013 1:27pm EDT

* Reuters is not responsible for the content in this press release.

Baron and Budd Lists Qualifications for Participating in GranuFlo Lawsuit

As lawsuits against the popular dialysis treatment progress, Baron and Budd provides information regarding lawsuit qualifications

The popular dialysis drug GranuFlo has allegedly been linked to increased risks of heart attack in patients. On March 29, 2012, the U.S. Food and Drug Administration (FDA) issued a Class 1 recall of GranuFlo along with its sister drug Naturalyte. According to the recall, “Inappropriate prescription of these products can lead to a high serum bicarbonate level in patients undergoing hemodialysis. This may contribute to metabolic alkalosis, which is a significant risk factor associated with low blood pressure, hypokalemia, hypoxemia, hypercapnia and cardiac arrhythmia, which, if not appropriately treated, may culminate in cardiopulmonary arrest.”

To respond to these serious risks associated with GranuFlo use, many allegedly injured patients have begun filing GranuFlo lawsuits to seek compensation for their health complications. The national law firm of Baron and Budd has responded by helping people understand the qualifications for a potential GranuFlo lawsuit.

At this time, lawyers at Baron and Budd are encouraging patients who have allegedly suffered serious injuries, such as heart attacks, while undergoing dialysis to contact them for a free consultation. If you or someone you know suffered from a heart attack after receiving dialysis, there is a possibility that GranuFlo was used during the dialysis process and may be one of the causes of your dangerous health issue.

While this Class 1 recall was initiated because of evidence that GranuFlo and Naturalyte involve a risk of heart attack, cardiopulmonary arrest – even death – during hemodialysis treatments, both GranuFlo and Naturalyte remain on the market today. GranuFlo is manufactured by Fresenius Medical Care (FMC), the world’s largest producer of all products and services related to dialysis; over one-third of the 400,000 or more Americans who receive dialysis treatments each year do so at Fresenius clinics where GranuFlo is often used. In addition, GranuFlo is used in many dialysis clinics in non-Fresenius centers.

If you or someone you know has received GranuFlo treatments during dialysis and suffered serious health issues, contact our GranuFlo lawyers today at 1.866.855.4556 or email us at For more information about GranuFlo lawyers and Baron and Budd, visit Baron and Budd’s website here:

For over 35 years, the lawyers at Baron and Budd have been protecting the rights of people against negligent companies. The firm has an accomplished track record of success when going up against large corporations such as pharmaceutical companies. Baron and Budd lawyers were involved in the litigation surrounding the diabetes drug Avandia, representing more than 7,000 patients harmed by Avandia use. Presently, Baron and Budd lawyers represent numerous states in lawsuits against the manufacturer GlaxoSmithKline. In the 1990s, the firm was highly involved in the litigation surrounding then-popular diet drug Fen-Phen, with a resulting global settlement valued at over $1.275 billion.

About Baron & Budd, P.C.

The law firm of Baron & Budd, P.C., with offices in Dallas, Baton Rouge, Austin and Los Angeles, is a nationally recognized law firm with a 35-year history of "Protecting What's Right" for people, communities and businesses harmed by negligence. Baron & Budd's size and resources enable the firm to take on large and complex cases. The firm represents individuals, governmental and business entities in areas as diverse as water contamination, Gulf oil spill, Qui Tam, California Proposition 65 violations, dangerous medications and medical devices, Chinese drywall, insurance claims, consumer fraud, securities fraud and asbestos-related illnesses such as mesothelioma.

Baron & Budd
Susan Knape, 214-629-0596
Amanda Billo, 214-991-1051

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.